These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26716908)

  • 1. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
    Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
    Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
    Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
    Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.
    Scheiter A; Evert K; Reibenspies L; Cigliano A; Annweiler K; Müller K; Pöhmerer LM; Xu H; Cui G; Itzel T; Materna-Reichelt S; Coluccio A; Honarnejad K; Teufel A; Brochhausen C; Dombrowski F; Chen X; Evert M; Calvisi DF; Utpatel K
    Mol Oncol; 2022 Mar; 16(5):1091-1118. PubMed ID: 34748271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
    Delogu S; Wang C; Cigliano A; Utpatel K; Sini M; Longerich T; Waldburger N; Breuhahn K; Jiang L; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
    Oncotarget; 2015 Feb; 6(4):2222-34. PubMed ID: 25537506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
    Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
    Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
    Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
    Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
    Zheng S; He S; Liang Y; Tan Y; Liu Q; Liu T; Lu X
    Mol Biomed; 2024 Apr; 5(1):13. PubMed ID: 38616230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
    Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
    Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.